Literature DB >> 8799169

Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.

Q Zhang1, I Nowak, E C Vonderheid, A H Rook, M E Kadin, P C Nowell, L M Shaw, M A Wasik.   

Abstract

Signaling through the interleukin 2 receptor (IL-2R) involves phosphorylation of several proteins including Jak3, STAT5, and, in preactivated cells, STAT3. In the present study, we examined the functional status of the IL-2R-associated Jak/STAT pathway in malignant T lymphocytes from advanced skin-based lymphomas: anaplastic large T-cell lymphoma (ALCL) and Sezary syndrome (SzS). Proliferation of three ALCL cell lines (PB-1, 2A, and 2B) was partially inhibited by rapamycin, a blocker of some of the signals mediated by IL-2R, but not by cyclosporin A, FK-506, and prednisone, which suppress signals mediated by the T-cell receptor. All the cell lines expressed on their surface the high-affinity IL-2R (alpha, beta, and gamma c chains). They showed basal, constitutive phosphorylation, and coassociation of Jak3, STAT5, and STAT3. Weak basal phosphorylation of IL-2R gamma c was also detected. In regard to SzS, peripheral blood mononuclear cells from 10 of 14 patients showed basal phosphorylation of Jak3, accompanied by phosphorylation of STAT5 in 9 patients, and STAT3 in 4 patients. However, in vitro overnight culture of SzS cells without exogenous cytokines resulted in markedly decreased Jak3 and STAT5 phosphorylation, which could be reversed by stimulation with IL-2. This indicates that the basal phosphorylation of Jak3 and STAT5 in freshly isolated SzS cells is induced rather than constitutive. The basal activation of the Jak/STAT pathway involved in IL-2R signal transduction in ALCL and SzS cells reported here suggests that this pathway may play a role in the pathogenesis of cutaneous T-cell lymphomas, although the mechanism (induced versus constitutive) may vary between different lymphoma types.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799169      PMCID: PMC38610          DOI: 10.1073/pnas.93.17.9148

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

1.  Differential effects of cytokines on proliferative response of human CD4+ T lymphocyte subsets stimulated via T cell receptor-CD3 complex.

Authors:  M A Wasik; C Morimoto
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

2.  Diagnostic and prognostic significance of Sézary cells in peripheral blood smears from patients with cutaneous T cell lymphoma.

Authors:  E C Vonderheid; E L Sobel; P C Nowell; J B Finan; M K Helfrich; D S Whipple
Journal:  Blood       Date:  1985-08       Impact factor: 22.113

Review 3.  Sézary syndrome: diagnosis, prognosis, and critical review of treatment options.

Authors:  J S Wieselthier; H K Koh
Journal:  J Am Acad Dermatol       Date:  1990-03       Impact factor: 11.527

Review 4.  Signaling through the hematopoietic cytokine receptors.

Authors:  J N Ihle; B A Witthuhn; F W Quelle; K Yamamoto; O Silvennoinen
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

5.  Diagnostic criteria in Sézary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma.

Authors:  R Willemze; W A van Vloten; J Hermans; M J Damsteeg; C J Meijer
Journal:  J Invest Dermatol       Date:  1983-11       Impact factor: 8.551

Review 6.  Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification.

Authors:  T Suchi; K Lennert; L Y Tu; M Kikuchi; E Sato; A G Stansfeld; A C Feller
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

7.  Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth.

Authors:  H Merz; A Fliedner; K Orscheschek; T Binder; W Sebald; H K Müller-Hermelink; A C Feller
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

8.  Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone.

Authors:  T H Davis; C C Morton; R Miller-Cassman; S P Balk; M E Kadin
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

9.  A clonal CD4-positive T-cell line established from the blood of a patient with Sézary syndrome.

Authors:  J T Abrams; S Lessin; S K Ghosh; W Ju; E C Vonderheid; P Nowell; G Murphy; B Elfenbein; E DeFreitas
Journal:  J Invest Dermatol       Date:  1991-01       Impact factor: 8.551

10.  IL-2 mRNA expression in Tac-positive malignant lymphomas.

Authors:  M Peuchmaur; D Emilie; M C Crevon; P Solal-Celigny; M C Maillot; G Lemaigre; P Galanaud
Journal:  Am J Pathol       Date:  1990-02       Impact factor: 4.307

View more
  63 in total

1.  Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray.

Authors:  S Li; D T Ross; M E Kadin; P O Brown; M A Wasik
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.

Authors:  Q Zhang; P N Raghunath; E Vonderheid; N Odum; M A Wasik
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

4.  Interleukin-16 as a marker of Sézary syndrome onset and stage.

Authors:  Jillian Richmond; Marina Tuzova; Ashley Parks; Natalie Adams; Elizabeth Martin; Marianne Tawa; Lynne Morrison; Keri Chaney; Thomas S Kupper; Clara Curiel-Lewandrowski; William Cruikshank
Journal:  J Clin Immunol       Date:  2010-09-28       Impact factor: 8.317

Review 5.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

6.  Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2(pan-p)) transform T cells independently of Jak/STAT activation.

Authors:  J C Mulloy; T S Migone; T M Ross; N Ton; P L Green; W J Leonard; G Franchini
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 7.  Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency.

Authors:  J J O'Shea; L D Notarangelo; J A Johnston; F Candotti
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

8.  Stat3 activation is required for cellular transformation by v-src.

Authors:  J F Bromberg; C M Horvath; D Besser; W W Lathem; J E Darnell
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

9.  Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Authors:  Michal Marzec; Krzysztof Halasa; Xiaobin Liu; Hong Y Wang; Mangeng Cheng; Donald Baldwin; John W Tobias; Stephen J Schuster; Anders Woetmann; Qian Zhang; Suzanne D Turner; Niels Ødum; Mariusz A Wasik
Journal:  J Immunol       Date:  2013-11-11       Impact factor: 5.422

Review 10.  Recent advances in the understanding of interleukin-2 signal transduction.

Authors:  F Gesbert; M Delespine-Carmagnat; J Bertoglio
Journal:  J Clin Immunol       Date:  1998-09       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.